NCT04294628
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 87 versions: 12 with changes below, 38 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 17, 2026 Show 5 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 38 words
- Secondary endpoints: 3 to 5
- Study description expanded, about 28 words
- Site details revised at 1 of 6 sites
- Notable Primary endpoints revised (2)
- Secondary endpoints revised (3)
- Minor Enrollment target: estimated 63 to confirmed 62
- Primary completion date changed from estimate of Dec 31, 2025 to Sep 2, 2025
- Study completion date: Dec 31, 2025 to Jan 19, 2027
- Minor Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography (Procedure), Magnetic Resonance… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography Test (Procedure)…v57
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 6 of 6 sites
Show 7 earlier versionsHide 7 earlier versions
- Notable Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v48
- Notable Eligibility criteria expanded, about 50 wordsv46
- Notable Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v45
- Minor Site details revised at 2 of 6 sitesv44
- Minor Site details revised at 1 of 6 sitesv43
- Minor Site details revised at 1 of 6 sitesv42
- Minor Site details revised at 1 of 6 sitesv39
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients receive trastuzumab deruxtecan intravenous (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiogram (ECHO) or multi-gated acquisition scan (MUGA), computed tomography (CT) or magnetic resonance imaging (MRI), biopsies, and collection of blood samples throughout the study.
Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan
Biologicals: Trastuzumab Deruxtecan
Sites
6 sites in 1 country